share_log

Roche's Genentech Receives FDA Approval For Vabysmo Prefilled Syringe (PFS) To Treat Three Leading Causes Of Vision Loss

Benzinga ·  Jul 5 01:57
  • Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness –
  • Designed to simplify administration, Vabysmo PFS provides retina specialists a ready-to-use option –
  • Vabysmo PFS will be available for people living with wet AMD, DME and RVO –
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment